Diagnostic et prise en charge des evenements indesirables severes survenant au decours des instillations endovesicales de BCG pour le traitement des tumeurs de vessie n'infiltrant pas le muscle (TVNIM)

摘要

BCG therapy, which is the standard treatment for non-muscle invasive bladder tumours with high risk of recurrence and progression, has potential life-threatening adverse effects (AEs).Rapid deterioration of general condition in a patient with history of bladder tumour should question about an ongoing treatment with BCG and specify the date of the last instillation. Trauma during catheterization and untreated concomitant urinary infection upon instillations are risk factors of severe AEs.